To include your compound in the COVID-19 Resource Center, submit it here.

Cx601: Phase I/II final data

Final data from an open-label, Spanish Phase I/II trial in 24 patients showed that Cx601 was safe with no treatment-related adverse events reported that indicated any clinical safety concerns at 6-month

Read the full 315 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE